Loading
A phase 2 trial of cetuximab, fOLFIRI (5-FU, leucovorin, irinotecan), bevacizumab (glioblastoma use) and sintilimab in colorectal cancer, run by Guangdong Provincial People's Hospital, now recruiting.
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial is a phase 2, randomised interventional study registered as NCT07722754 by Guangdong Provincial People's Hospital, with a registry enrolment figure of 160 participants, started 2026-07-23 and due to reach its primary completion in 2028-07-31. Interventions recorded: Cetuximab; Irinotecan; Bevacizumab; Sintilimab. Conditions listed: Colorectal Neoplasms Malignant; Neoplasm, Metastatic. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: "* Metastatic and unresectable colorectal adenocarcinom;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.